Presentation TCT 2015 Three to Six Months of DAPT Is My Practice Even in Very Complex Cases: Heres Why Presenter: Ricardo Lluberas, Roxana Mehran, Jamil Abdalla Saad, Fausto Feres October 11, 2015
Presentation TCT 2015 From WOEST, DAPT, and PEGASUS to GLOBAL LEADERS and TWILIGHT: What Answers Can We Expect (and Not Expect) From GLOBAL LEADERS and TWILIGHT? Presenter: Ori Ben-Yehuda, Ajay J. Kirtane, Roxana Mehran October 11, 2015
Presentation TCT 2015 Featured Lecture: Should Stent Design Impact DAPT Duration Decisions? Insights From the DAPT Study Presenter: John A. Bittl, E. Magnus Ohman, James B. Hermiller Jr October 11, 2015
Presentation TCT 2015 Debate: The Case for Short-term DAPT in Most Patients! Presenter: Regina Deible, Gennaro Giustino October 11, 2015
Presentation TCT 2015 Featured Lecture: New DAPT Duration Recommendations Presenter: John A. Bittl, E. Magnus Ohman October 11, 2015
Presentation TCT 2015 Debate: The Case for Long-term DAPT After Stenting In Most Patients! Presenter: Regina Deible, Daniel I. Simon October 11, 2015
Presentation TCT 2015 Debate: What Is the Ideal Duration of DAPT After DES? Shorter Is Best (for Most)! Presenter: John A. Bittl, E. Magnus Ohman, Hyeon-Cheol Gwon October 11, 2015
Presentation TCT 2015 Debate: What Is the Ideal Duration of DAPT After DES? Longer Is Better (for Most)! Presenter: John A. Bittl, E. Magnus Ohman, David P. Lee October 11, 2015
Presentation TCT 2015 Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Clopidogrel and Prasugrel (DAPT Trial)! Presenter: C. Michael Gibson, Marco Valgimigli, Robert W. Yeh October 11, 2015
Presentation TCT 2015 Debate: Are Bioabsorbable Polymers Preferable to Durable Polymers for Efficacy, Safety, or Required DAPT Duration? No, This Theoretical Goal Does Not Hold Up Under Scrutiny! Presenter: Stephen G. Ellis, John A. Ormiston, Tullio Palmerini October 11, 2015
Presentation TCT 2015 Debate: Are Bioabsorbable Polymers Preferable to Durable Polymers for Efficacy, Safety, or Required DAPT Duration? Yes, Eliminating the Polymer to Leave Behind a Bare-Metal Stent Surface Is a Desirable and Clinically Meaningful Goal! Presenter: Stephen G. Ellis, John A. Ormiston, Robert A. Byrne October 11, 2015
News Conference News TCT 2015 Novel Devices Present New Treatment Options for STEMI Yael L. Maxwell October 11, 2015
News Conference News TCT 2015 Experts Debate Optimal Pharmacologic Approach for STEMI Patients October 11, 2015
News Daily News Subestudio ADAPT-DES: Los Cambios de la Práctica podrían disminuir aún más los ya bajos índices de trombosis del stent Yael L. Maxwell October 09, 2015
News Daily News ADAPT-DES Substudy: Practice Changes May Decrease Already Low Stent Thrombosis Rates Even Further Yael L. Maxwell October 09, 2015
News Daily News No Interplay Between Access Site, Cangrelor Effects in PCI Patients Caitlin E. Cox October 06, 2015
News Industry News Boston Scientific Receives FDA Approval For SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System October 05, 2015
News Daily News Good Outcomes of Novel Bioresorbable-Polymer SES Persist at 2 Years Yael L. Maxwell October 02, 2015